Glutamatergic neurons in the medial prefrontal cortex mediate the formation and retrieval of cocaine-associated memories in mice.


Journal

Addiction biology
ISSN: 1369-1600
Titre abrégé: Addict Biol
Pays: United States
ID NLM: 9604935

Informations de publication

Date de publication:
01 2020
Historique:
received: 17 07 2018
revised: 04 12 2018
accepted: 10 01 2019
pubmed: 9 2 2019
medline: 11 2 2021
entrez: 9 2 2019
Statut: ppublish

Résumé

In drug addiction, environmental stimuli previously associated with cocaine use readily elicit cocaine-associated memories, which persist long after abstinence and trigger cocaine craving and consumption. Although previous studies suggest that the medial prefrontal cortex (mPFC) is involved in the expression of cocaine-addictive behaviors, it remains unclear whether excitatory and inhibitory neurons in the mPFC are causally related to the formation and retrieval of cocaine-associated memories. To address this issue, we used the designer receptors exclusively activated by designer drugs (DREADD) technology combined with a cocaine-induced conditioned place preference (CPP) paradigm. We suppressed mPFC neuronal activity in a cell-type- and timing-dependent manner. C57BL/6J wild-type mice received bilateral intra-mPFC infusion of an adeno-associated virus (AAV) expressing inhibitory DREADD (hM4Di) under the control of CaMKII promotor to selectively suppress mPFC pyramidal neurons. GAD67-Cre mice received bilateral intra-mPFC infusion of a Cre-dependent AAV expressing hM4Di to specifically silence GABAergic neurons. Chemogenetic suppression of mPFC pyramidal neurons significantly attenuated both the acquisition and expression of cocaine CPP, while suppression of mPFC GABAergic neurons affected neither the acquisition nor expression of cocaine CPP. Moreover, chemogenetic inhibition of mPFC glutamatergic neurons did not affect the acquisition and expression of lithium chloride-induced conditioned place aversion. These results suggest that the activation of glutamatergic, but not GABAergic, neurons in the mPFC mediates both the formation and retrieval of cocaine-associated memories.

Identifiants

pubmed: 30734456
doi: 10.1111/adb.12723
doi:

Substances chimiques

Dopamine Uptake Inhibitors 0
Cocaine I5Y540LHVR

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12723

Subventions

Organisme : Grant-in-Aid for Scientific Research (B) from the Japan Society for the Promotion of Science
ID : 18H02523
Pays : International
Organisme : Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science
ID : 15K06765
Pays : International
Organisme : Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science
ID : 18K06520
Pays : International
Organisme : The Naito Foundation (K.K.)
Pays : International
Organisme : Smoking Research Foundation (K.K.)
Pays : International
Organisme : Hoansha Foundation (K.K.)
Pays : International

Informations de copyright

© 2019 Society for the Study of Addiction.

Références

Tzschentke TM. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol. 2007;12(3-4):227-462.
Isaac WL, Nonneman AJ, Neisewander J, Landers T, Bardo MT. Prefrontal cortex lesions differentially disrupt cocaine-reinforced conditioned place preference but not conditioned taste aversion. Behav Neurosci. 1989;103(2):345-355.
Tzschentke TM, Schmidt WJ. Functional heterogeneity of the rat medial prefrontal cortex: effects of discrete subarea-specific lesions on drug-induced conditioned place preference and behavioural sensitization. Eur J Neurosci. 1999;11(11):4099-4109.
Otis JM, Dashew KB, Mueller D. Neurobiological dissociation of retrieval and reconsolidation of cocaine-associated memory. J Neurosci. 2013;33(3):1271-1281a.
Shinohara F, Kamii H, Minami M, Kaneda K. The role of dopaminergic signaling in the medial prefrontal cortex for the expression of cocaine-induced conditioned place preference in rats. Biol Pharm Bull. 2017;40(11):1983-1989.
Dong Y, Nasif FJ, Tsui JJ, et al. Cocaine-induced plasticity of intrinsic membrane properties in prefrontal cortex pyramidal neurons: adaptations in potassium currents. J Neurosci. 2005;25(4):936-940.
Huang CC, Lin HJ, Hsu KS. Repeated cocaine administration promotes long-term potentiation induction in rat medial prefrontal cortex. Cereb Cortex. 2007;17(8):1877-1888.
Muñoz-Cuevas FJ, Athilingam J, Piscopo D, Wilbrecht L. Cocaine-induced structural plasticity in frontal cortex correlates with conditioned place preference. Nat Neurosci. 2013;16(10):1367-1369.
Nasif FJ, Hu XT, White FJ. Repeated cocaine administration increases voltage-sensitive calcium currents in response to membrane depolarization in medial prefrontal cortex pyramidal neurons. J Neurosci. 2005a;25(14):3674-3679.
Nasif FJ, Sidiropoulou K, Hu XT, White FJ. Repeated cocaine administration increases membrane excitability of pyramidal neurons in the rat medial prefrontal cortex. J Pharmacol Exp Ther. 2005b;312(3):1305-1313.
Otis JM, Mueller D. Reversal of cocaine-associated synaptic plasticity in medial prefrontal cortex parallels elimination of memory retrieval. Neuropsychopharmacology. 2017;42(10):2000-2010.
Pena-Bravo JI, Reichel CM, Lavin A. Abstinence from cocaine-induced conditioned place preference produces discrete changes in glutamatergic synapses onto deep layer 5/6 neurons from prelimbic and infralimbic cortices. eNeuro. 2017;4(6):ENEURO.0308-ENEU17.2017.
Campanac E, Hoffman DA. Repeated cocaine exposure increases fast-spiking interneuron excitability in the rat medial prefrontal cortex. J Neurophysiol. 2013;109(11):2781-2792.
Slaker M, Churchill L, Todd RP, et al. Removal of perineuronal nets in the medial prefrontal cortex impairs the acquisition and reconsolidation of a cocaine-induced conditioned place preference memory. J Neurosci. 2015;35(10):4190-4202.
Chefer VI, Wang R, Shippenberg TS. Basolateral amygdala-driven augmentation of medial prefrontal cortex GABAergic neurotransmission in response to environmental stimuli associated with cocaine administration. Neuropsychopharmacology. 2011;36(10):2018-2029.
Miller CA, Marshall JF. Altered prelimbic cortex output during cue-elicited drug seeking. J Neurosci. 2004;24(31):6889-6897.
Higo S, Akashi K, Sakimura K, Tamamaki N. Subtypes of GABAergic neurons project axons in the neocortex. Front Neuroanat. 2009;3:25.
Franklin KBJ, Paxinos G. The Mouse Brain in Stereotaxic Coordinates. 3rd ed. Elsevier: Burlington, MA; 2007.
Zhang T, Deyama S, Domoto M, et al. Activation of GABAergic neurons in the nucleus accumbens mediates the expression of cocaine-associated memory. Biol Pharm Bull. 2018;41(7):1084-1088.
Tzschentke TM. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol. 1998;56(6):613-672.
Sanjakdar SS, Maldoon PP, Marks MJ, et al. Differential roles of α6β2* and α4β2* neuronal nicotinic receptors in nicotine- and cocaine-conditioned reward in mice. Neuropsychopharmacology. 2015;40(2):350-360.
Gunaydin LA, Grosenick L, Finkelstein JC, et al. Natural neural projection dynamics underlying social behavior. Cell. 2014;157(7):1535-1551.
Dong Y, White FJ. Dopamine D1-class receptors selectively modulate a slowly inactivating potassium current in rat medial prefrontal cortex pyramidal neurons. J Neurosci. 2003;23(7):2686-2695.
Witkowski G, Szulczyk B, Rola R, Szulczyk P. D1 dopaminergic control of G protein-dependent inward rectifier K+ (GIRK)-like channel current in pyramidal neurons of the medial prefrontal cortex. Neuroscience. 2008;155(1):53-63.
Chen G, Greengard P, Yan Z. Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex. Proc Natl Acad Sci U S A. 2004;101(8):2596-2600.
Wang J, O'Donnell P. D1 dopamine receptors potentiate NMDA-mediated excitability increase in layer V prefrontal cortical pyramidal neurons. Cereb Cortex. 2001;11(5):452-462.
Buchta WC, Mahler SV, Harlan B, Aston-Jones GS, Riegel AC. Dopamine terminals from the ventral tegmental area gate intrinsic inhibition in the prefrontal cortex. Physiol Rep. 2017;5(6):e13198.
Ventura R, Morrone C, Puglisi-Allegra S. Prefrontal/accumbal catecholamine system determines motivational salience attribution to both reward- and aversion-related stimuli. Proc Natl Acad Sci U S A. 2007;104(12):5181-5186.
Popescu AT, Zhou MR, Poo MM. Phasic dopamine release in the medial prefrontal cortex enhances stimulus discrimination. Proc Natl Acad Sci U S A. 2016;113(22):E3169-E3176.
Calipari ES, Bagot RC, Purushothaman I, et al. In vivo imaging identifies temporal signature of D1 and D2 medium spiny neurons in cocaine reward. Proc Natl Acad Sci U S A. 2016;113(10):2726-2731.
Stefanik MT, Moussawi K, Kupchik YM, et al. Optogenetic inhibition of cocaine seeking in rats. Addict Biol. 2013;18(1):50-53.
McGlinchey EM, James MH, Mahler SV, Pantazis C, Aston-Jones G. Prelimbic to accumbens core pathway is recruited in a dopamine-dependent manner to drive cued reinstatement of cocaine seeking. J Neurosci. 2016;36(33):8700-8711.
Fitzgerald MK, Otis JM, Mueller D. Dissociation of β1- and β2-adrenergic receptor subtypes in the retrieval of cocaine-associated memory. Behav Brain Res. 2016;296:94-99.
Otis JM, Fitzgerald MK, Mueller D. Inhibition of hippocampal β-adrenergic receptors impairs retrieval but not reconsolidation of cocaine-associated memory and prevents subsequent reinstatement. Neuropsychopharmacology. 2014;39(2):303-310.
Otis JM, Mueller D. Inhibition of β-adrenergic receptors induces a persistent deficit in retrieval of a cocaine-associated memory providing protection against reinstatement. Neuropsychopharmacology. 2011;36(9):1912-1920.
Miller CA, Marshall JF. Altered Fos expression in neural pathways underlying cue-elicited drug seeking in the rat. Eur J Neurosci. 2005;21(5):1385-1393.
Hangya B, Pi HJ, Kvitsiani D, Ranade SP, Kepecs A. From circuit motifs to computations: mapping the behavioral repertoire of cortical interneurons. Curr Opin Neurobiol. 2014;26:117-124.
Tremblay R, Lee S, Rudy B. GABAergic interneurons in the neocortex: from cellular properties to circuits. Neuron. 2016;91(2):260-292.
Pi HJ, Hangya B, Kvitsiani D, Sanders JI, Huang ZJ, Kepecs A. Cortical interneurons that specialize in disinhibitory control. Nature. 2013;503(7477):521-524.
Lee AT, Vogt D, Rubenstein JL, Sohal VS. A class of GABAergic neurons in the prefrontal cortex sends long-range projections to the nucleus accumbens and elicits acute avoidance behavior. J Neurosci. 2014;34(35):11519-11525.
Jiang ZC, Pan Q, Zheng C, Deng XF, Wang JY, Luo F. Inactivation of the prelimbic rather than infralimbic cortex impairs acquisition and expression of formalin-induced conditioned place avoidance. Neurosci Lett. 2014;569:89-93.
Gomez JL, Bonaventura J, Lesniak W, et al. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. Science. 2017;357(6350):503-507.
Padovan-Hernandez Y, Knackstedt LA. Dose-dependent reduction in cocaine-induced locomotion by clozapine-N-oxide in rats with a history of cocaine self-administration. Neurosci Lett. 2018;674:132-135.
Hsiang HL, Epp JR, van den Oever MC, et al. Manipulating a “cocaine engram” in mice. J Neurosci. 2014;34(42):14115-14127.
Wayman WN, Woodward JJ. Chemogenetic excitation of accumbens-projecting infralimbic cortical neurons blocks toluene-induced conditioned place preference. J Neurosci. 2018;38(6):1462-1471.

Auteurs

Tong Zhang (T)

Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.

Junko Yanagida (J)

Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.

Hironori Kamii (H)

Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Shintaro Wada (S)

Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.

Masaki Domoto (M)

Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.

Hitoki Sasase (H)

Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.

Satoshi Deyama (S)

Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.

Takeshi Takarada (T)

Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Eiichi Hinoi (E)

Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.

Kenji Sakimura (K)

Department of Cellular Neurobiology, Brain Research Institute, Niigata University, Niigata, Japan.

Akihiro Yamanaka (A)

Department of Neuroscience II, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan.

Takashi Maejima (T)

Department of Integrative Neurophysiology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.

Michihiro Mieda (M)

Department of Integrative Neurophysiology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.

Takeshi Sakurai (T)

Department of Integrative Neurophysiology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
International Institute for Integrative Sleep Medicine, University of Tsukuba, Tsukuba, Japan.

Naoya Nishitani (N)

Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.

Kazuki Nagayasu (K)

Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.

Shuji Kaneko (S)

Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.

Masabumi Minami (M)

Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Katsuyuki Kaneda (K)

Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH